Weekly Funding Roundup: $2.1B Drug Discovery Bet, Alphabet's Yen Bond Push & More

Isomorphic Labs, founded by Sir Demis Hassabis, secured a $2.1 billion Series B funding round to expand its AI-driven drug discovery platform, IsoDDE. The round included participation from Thrive Capital, Alphabet’s GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, reflecting strong investor confidence in AI-driven biotech solutions. The funds will accelerate IsoDDE’s development, advance internal drug programs into clinical trials, and expand hiring across London, Cambridge (Massachusetts), and Lausanne. The company’s partnerships with Novartis, Eli Lilly, and Johnson & Johnson provide validation for its AI-guided drug design approach, which aims to reduce the time and cost of traditional lab work. Isomorphic’s clinical collaborations demonstrate real-world application beyond theoretical benchmarks, addressing investor skepticism about AI’s role in drug development. Separately, Alphabet announced plans to issue its first yen-denominated bond, targeting 100 billion yen (~$670 million) to support AI infrastructure spending. The move marks Alphabet’s first foray into Japanese debt markets, reflecting its global expansion strategy as AI-related capital expenditures approach $180–190 billion annually. Investors are increasingly prioritizing companies with clear revenue models, commercial partnerships, and scalable AI infrastructure over growth projections alone. Global venture capital and growth funding rebounded to $16 billion in 2025 after declines in 2023, but larger rounds—like Isomorphic’s—now dominate the market, signaling a shift toward fewer, high-potential bets. The trend underscores a broader industry focus on execution and monetization strategies.